Inbeeo

What Inbeeo does

Inbeeo is a London-based management consulting firm providing strategic market access and pricing services to pharmaceutical and medical technology companies. Founded in 2018 by Hervé Lilliu and now part of the Enosium Life Science group, the firm operates a B2B professional services model with project-based consulting fees, delivering engagements that span the full product lifecycle from early clinical development through launch, pricing, reimbursement negotiation, and loss-of-exclusivity. Five service pillars—Define Value Strategy, Optimize Evidence Plan, Price Asset Right, Communicate Value, and Navigate Access Policies—are delivered alongside three proprietary products: i-vbp® (a cloud-based Multi-Criteria Decision Analysis application for quantitative value assessment), i-pec® (a curated network of more than 100 international payer, policy, clinician, and patient experts), and i-las® (an advisory forum convening global market access leaders).

The firm's revenue is generated through bespoke, non-publicly-priced consulting engagements for enterprise pharmaceutical and MedTech clients, with delivery supported by partner consultancies in geographies outside its core European, US, Canada, China, and Japan footprint. Customer evidence centres on engagements with Top-5 global pharmaceutical companies, large biotechs, specialty pharma, and MedTech suppliers across therapeutic areas including rare diseases, ATMPs, gene and cell therapies, oncology, CNS, and digital therapeutics. Credibility is reinforced by the UK Queen's Award for Enterprise in Innovation/R&D and a 2025 EcoVadis Silver sustainability rating, while the 2024 acquisition by Enosium Life Science integrates Inbeeo with Vyoo Agency (HEOR/Market Access) and Epione (Scientific Communication) into a multi-specialist life sciences services group operating from Inbeeo's headquarters at 14 Bedford Square, London.

Name

Inbeeo

Legal name

Inbeeo Limited

Website

https://inbeeo.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Inbeeo is a London-based pharma and MedTech consulting firm delivering strategic market access, pricing, and value-communication engagements, supported by three proprietary platforms—i-vbp®, i-pec®, and i-las®—and operating as part of Enosium Life Science.

Ownership category

akta.pro rank

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Strategic Consulting Services: B2B professional consulting engagements providing tailor-made solutions for market access and pricing challenges for pharmaceutical and MedTech companies. Engagements cover the full product lifecycle from early clinical development through launch and lifecycle management. Revenue is generated through project-based consulting fees.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Inbeeo delivers tailor-made strategy consulting to help pharmaceutical companies and medical technology suppliers realize the full value of their health technologies. The firm operates across the full product lifecycle—from early clinical development through launch and lifecycle management—providing value strategy, evidence planning, pricing, value communication, and access policy navigation. Services are powered by proprietary tools (i-vbp®, i-pec®, i-las®) and a global network of payer and clinical experts.

Product overview

Inbeeo is a strategic market access and pricing consulting firm for pharmaceutical and MedTech companies. The company offers three core proprietary products: i-vbp® (a cloud-based MCDA value assessment framework application), i-pec® (a payer and expert council network of 100+ international experts), and i-las® (a collaborative discussion platform for market access leaders). These tools are complemented by five consulting service areas: Define Your Value Strategy, Optimize Your Evidence Plan, Price Your Asset Right, Communicate the Value, and Navigate Access Policies. The integrated offering enables life sciences companies to create optimal value from innovative products across the entire product lifecycle from early development through launch and lifecycle management.

Differentiator

Problem solved

Functional benefit

Brands

• i-vbp: Cloud-based value-based pricing application that enables generation of custom value frameworks to demonstrate the full value of pharmaceutical and MedTech assets using MCDA methodology.
• i-pec
• i-las

Products and services

• Strategic Market Access & Pricing Consulting Tailor-made consulting engagements that help pharmaceutical companies and medical technology suppliers realize the full value of their health technologies, structured around five integrated service areas: Define Your Value Strategy, Optimize Your Evidence Plan, Price Your Asset Right, Communicate the Value, and Navigate Access Policies. Services span EU4, UK, US, Canada, China, Japan, and additional partner-supported geographies.
• i-vbp® (Interactive Value-Based Pricing) Easy-to-use and secure cloud-based application that enables the generation of custom value frameworks tailored to demonstrate the full value of healthcare assets. Uses MCDA methodology to distil elements of value into an aggregated value summary to quantitatively compare assets on a value spectrum between 0 and 1, incorporating quality of evidence as a modifier and applying monetary value based on willingness-to-pay thresholds or price benchmarks.
• i-pec® (Payer and Expert Council) A network of more than 100 international payers and experts with decades of experience in HTA, P&R and HEOR in their local markets. The network includes policy makers, payers, clinicians and patient experts who can be engaged to provide perspective on value, access, and pricing questions across multiple geographies.
• i-las® (Interactive Leaders Advisory Series) A platform bringing together global market access leaders for collaborative discussions on industry-wide topics and challenges, designed to foster cross-industry dialogue on market access strategy.

Quantifiable outcome

• NICE cited Inbeeo's DELPHI survey report 17 times as key to reversing negative recommendation for biologic osteoporosis treatment in England
• +1 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Enosium Life SciencecoreStrategic or Co-development PartnerInbeeo is part of Enosium Life Science, an integrated life sciences services group. The acquisition positions Inbeeo as the strategic pricing and market access arm of the group, complementing Vyoo Agency (Strategic Health Economics and Market Access) and Epione (Scientific Communication). This integration offers clients access to a broader, connected range of capabilities across the healthcare product value chain.
• Vyoo AgencyminorStrategic or Co-development PartnerPart of Enosium Life Science group, Vyoo Agency provides Strategic Health Economics and Market Access services, complementing Inbeeo's offerings within the integrated group.
• EpioneminorStrategic or Co-development PartnerPart of Enosium Life Science group, Epione provides Scientific Communication services, complementing Inbeeo's market access and pricing offerings within the integrated group.
• Boutique Consultancies and Independent ConsultantsminorChannel Partner/ Reseller/ DistributorInbeeo partners with boutique consultancies and independent consultants globally to offer in-market expertise and specialist knowledge across various geographies beyond their core European, US, Canada, China, and Japan markets.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• IQVIA: World's largest life sciences services and consulting provider, offering technology, data, and advisory services including market access and HEOR. Represents the scaled incumbent against which Inbeeo competes on enterprise mandates.

Direct peers

• Avalere Health: US-based healthcare strategy and policy consultancy advising biopharma on market access, pricing, and value evidence. Direct peer with significant overlap in payer landscape and HTA advisory work.
• Trinity Partners: Life sciences strategy consultancy focused on commercial and market access strategy for global biopharma. Comparable on therapeutic-area depth and engagement-style with global pharma clients.
• Putnam Associates: US-headquartered pharma strategy and market access consultancy serving global pharmaceutical and biotech clients on pricing, reimbursement, and value strategy. Closest direct peer to Inbeeo in therapeutic focus and boutique delivery model, though larger in scale.
• Xcenda: Market access, health economics, and reimbursement consulting arm of Cencora (formerly AmerisourceBergen). Competes directly with Inbeeo on payer engagement, HEOR modeling, and value communications for pharma manufacturers.
• Evidera: Multi-HEOR and market access consultancy within the PPD clinical research business of Thermo Fisher Scientific. Directly comparable in HEOR, value evidence generation, and pricing support for global pharma clients.
• Lattice (formerly PRMA Consulting): Specialist market access and HEOR consultancy supporting pharma clients globally on pricing, reimbursement, and value strategy. Closely comparable boutique peer with strong international delivery.
• Charles River Associates (CRA) – Life Sciences: CRA's Life Sciences practice provides commercial, pricing, and market access strategy consulting to pharma and biotech. Closely comparable on strategy, pricing, and litigation-support work, but with the resources of a public advisory firm.

Regional players

• MAP BioPharma: UK-based market access consultancy providing pricing, reimbursement, and HTA navigation services to pharma. Direct peer for European market access work, with similar geographic focus to Inbeeo's UK-EU base.

Emerging players

• Precision Medicine Group: Specialized life sciences services provider including market access, HEOR, and commercialization support. Comparable on end-to-end access and commercialization support, but with a broader biomarker/Precision Medicine service mix.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/inbeeo

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inbeeo